Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting.
BACKGROUND
The global burden of disease attributable to chronic hepatitis C virus (HCV) is very large, yet the uptake of curative antiviral therapies remains very low, reflecting the marginalized patient population and the arduous nature of current treatments.


METHODS
The safety and effectiveness of a nurse-led model of care of inmates with chronic HCV was evaluated in 3 Australian correctional centers. The model featured protocol-driven assessment, triage, and management of antiviral therapy by specifically trained nurses, with specialist physician support utilizing telemedicine. Outcomes were evaluated qualitatively with key informant interviews, and quantitatively with patient numbers completing key clinical milestones and adverse events.


RESULTS
A total of 391 patients with chronic HCV infection were enrolled, of whom 141 (36%) completed the clinical and laboratory evaluations for eligibility for antiviral therapy over 24 months. Treatment was initiated in 108 patients (28%), including 85 (79%) triaged for specialist review conducted by telemedicine only. The demographic and clinical characteristics of the patients who entered the model and completed workup and those who initiated treatment featured a high prevalence of individuals of indigenous background, injection drug users, and those with psychiatric disorder. Serious adverse events occurred in 13 of 108 treated patients (12%) with discontinuation in 8 (7%). The sustained virologic response rate among those with complete follow-up data (n=68) was 69%, and by intention-to treat analysis was 44%.


CONCLUSIONS
This nurse-led and specialist-supported assessment and treatment model for inmates with chronic HCV offers potential to substantively increase treatment uptake and reduce the burden of disease.
Inflammation and Infection Research Centre, School of Medical Sciences, University of New South Wales,Sydney, Australia. a.lloyd@unsw.edu.au
Andrew R
AR
Lloyd
Jac
J
Clegg
Jens
J
Lange
Aleta
A
Stevenson
Jeffrey J
JJ
Post
David
D
Lloyd
Giulia
G
Rudge
Leng
L
Boonwaat
Gary
G
Forrest
Jenny
J
Douglas
Denise
D
Monkley
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001315:Australia; D005260:Female; D019698:Hepatitis C, Chronic / Q000628:therapy*; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced; D009726:Nurses; D011329:Prisoners; D011330:Prisons; D015397:Program Evaluation; D019114:Remote Consultation; D017216:Telemedicine; D016896:Treatment Outcome
D000998:Antiviral Agents